NasdaqGS:GILDBiotechs
Is Gilead Sciences (GILD) Overvalued Following Its Trodelvy Europe Expansion Win?
Gilead Sciences (GILD) is in focus after the European Medicines Agency’s Committee for Medicinal Products for Human Use backed the use of Trodelvy plus Keytruda for certain untreated PD-L1 positive metastatic triple-negative breast cancer patients.
See our latest analysis for Gilead Sciences.
The Trodelvy news lands at a time when Gilead Sciences’ share price has a year to date gain of 7.34% and a 1 year total shareholder return of 18.48%, alongside a very strong 5 year total shareholder...